Related Experiment Video
Updated: May 12, 2026

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
[Cardiovascular complications in immune mediated diseases]
1Service de rhumatologie, Département de méredecine interne, HUG, 1211 Genève 14. axel.finckh@hcuge.ch
Insights
Immune-mediated diseases increase cardiovascular risk due to chronic inflammation. Targeting inflammation may reduce cardiovascular complications in these patients.
Area of Science:
- Immunology
- Cardiology
- Inflammation Research
Context:
- Immune-mediated diseases are associated with a higher incidence of major cardiovascular events and mortality.
- Chronic inflammation is a key factor contributing to the elevated cardiovascular risk in these conditions.
Purpose:
- To review epidemiological data linking immune-mediated diseases with increased cardiovascular risk.
- To elucidate the role of inflammation in the development of cardiovascular complications.
- To evaluate the potential of anti-inflammatory therapies for mitigating cardiovascular risk.
Summary:
- Epidemiological studies consistently show a link between immune-mediated diseases and heightened cardiovascular risk.
- Chronic inflammation plays a causal role in the pathogenesis of cardiovascular complications in immune-mediated diseases.
- Evidence suggests that reducing inflammation through targeted therapies can decrease the occurrence of cardiovascular events.
Impact:
- Highlights the critical role of inflammation in cardiovascular disease associated with immune-mediated conditions.
- Provides a basis for exploring and implementing anti-inflammatory strategies to improve cardiovascular outcomes.
- Emphasizes the need for integrated care approaches addressing both immune and cardiovascular health.
Abstract:
Immune mediated diseases carry an increased risk of major cardiovascular events (CV) and an increased risk of CV mortality. The increased CV risk appears to be linked directly to chronic inflammation. Various studies have demonstrated that reducing inflammation reduces the incidence of CV complications. We review the epidemiological evidence linking immune mediated diseases and increased CV risk, discuss the causal role of inflammation in the etiopathogenesis and appraise some potential benefits of specific anti-inflammatory therapies.
Related Concept Videos
Hypersensitivity Reactions: Immune-Complex Reactions
Myocarditis III: Medical Management
Complications of Diabetes Mellitus
Myocarditis I: Introduction
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Rheumatic Heart Disease III: Medical Management
